Phase II trial of vinorelbine tartrate in patients with treatment-naïve metastatic melanoma

Anti-Cancer Drugs

Volumn 16, Issue 1, 2005, Pages 53-57

  Jimeno, Antonio ^a,b   Hitt, Ricardo ^a   Quintela Fandino, Miguel ^a   Cortés Funes, Hernán ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

First line; Metastatic melanoma; Phase II; Vinorelbine

Indexed keywords

NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION COMPLICATION; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 12544252341     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200501000-00007     Document Type: Article

References (22)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72:3091-3098.
3. Falkson CI, Falkson HC. Prognostic factors in metastatic malignant melanoma. An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972-1992. Oncology 1998; 55:59-64.
4. Brand CU, Ellwanger U, Stroebel W, Meier F. Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79:2345-2353.
5. Kirkwood JM. Systemic therapy of melanoma. Curr Opin Oncol 1994; 6:204-211.
6. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
7. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21-34.
8. Jungnelius U, Ringborg U, Aamdal S, Mattsson J, Stierner U, Ingvar C, et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer 1998; 34:1368-1374
9. Ringborg U, Jungnelius U, Hansson J, Strander H. Dacarbazine-vindesine- cisplatin in disseminated malignant melanoma. A phase I-II trial. Am J Clin Oncol 1990; 13:214-217.
10. Reinhold U, Bruske T, Kreysel HW. Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma. Eur J Cancer 1996; 32A:180.
11. Retsas S, Peat I, Ashford R, Coe M, Maher J, Drury A, et al. Update results of vindesine as a single agent in the therapy of advanced malignant melanoma. Cancer Treat Rev 1980; 7(suppl 1):87-90.
12. Retsas S, Newton KA, Westbury G, Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 1979; 2:257-260.
13. Photiou A, Sheikh MN, Bafaloukos D, Retsas S. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol 1992; 118:249-254.
14. Photiou A, Shah P, Leong LK, Moss J, Retsas S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 1997; 33:463-470,
15. Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs 1996; 7:161-165.
16. Feun LG, Savaraj N, Hurley J, Marini A, Lai S. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer 2000; 88:584-588
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
18. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45:537-547.
19. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Soc Stat Ass 1958; 53:447
20. Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, et al. A phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer 2004; 100:1699-1704.
21. Toma S, Ugolini D, Palumbo R. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? [Review]. Int J Oncol 1999; 15:321-337.
22. Lens MB, Reiman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer 2003; 98:1 355-1361.